Synmosa Biopharma Listed by dragonforce Ransomware Group: Ransomware Claim — What’s Alleged & What To Do

On April 27, 2026, the ransomware group dragonforce listed Synmosa Biopharma on its leak site, claiming to have carried out a ransomware attack that resulted in the exfiltration of internal files. The number of individuals whose information may be involved remains unknown, and no further details about the scope or contents of the data have been made public. This development raises practical questions for anyone connected to the company through employment, partnerships, clinical work, or supply-chain relationships, as internal pharmaceutical records can contain sensitive operational and personal information.

Breaking down the breach

The only confirmed public information is the listing itself, reported on April 27, 2026. The group claims responsibility for a ransomware attack in which internal files were exfiltrated. No figure has been released for the volume of data, the number of people affected, or the precise timing of the intrusion. The method is described only as a ransomware attack; additional technical details have not been disclosed.

Who is dragonforce?

Dragonforce is a ransomware group that follows a double-extortion model: it typically encrypts systems and also removes copies of data, then lists victim organisations on a public leak site when ransom demands are not met. The group’s listings serve as a public claim of responsibility rather than independently verified proof of the underlying incident. Similar claims by the same actor have appeared against organisations in multiple sectors in recent years.

Who is Synmosa Biopharma?

Synmosa Biopharma is a Taiwan-based specialty pharmaceutical company established in 1980. It operates across agent services, manufacturing, original equipment manufacturing, and research and development. Companies of this type routinely maintain records related to product development, regulatory submissions, manufacturing processes, and business relationships with suppliers, clinical sites, and employees.

What was likely exposed

The listing states that internal files were exfiltrated. No inventory of specific file types or data categories has been released. Organisations in the pharmaceutical sector commonly store employee records, partner and vendor information, research documentation, and regulatory correspondence; whether any of these categories are present in the exfiltrated material remains unconfirmed.

Why it matters

Pharmaceutical companies hold data that can affect both commercial operations and individuals. Exposure of internal files could reveal details about ongoing research, manufacturing controls, or personal information belonging to staff and collaborators. Until the contents are clarified or ruled out, affected parties face uncertainty about potential misuse of any information that may have been taken.

If your data was in this claimed breach

Because the exact data types remain undisclosed, individuals connected to Synmosa Biopharma should treat the incident as a prompt to review their own exposure rather than assume specific records were involved.

• Monitor official communications from the company for any guidance it may issue.
• Change passwords for any accounts linked to the organisation and enable multi-factor authentication where available.
• Watch for unusual activity in financial or medical accounts that could be tied to employment or partnership records.
• Run a free exposure scan of your email address against known breach data to check for prior appearances of your information.

AICompiled with AI assistance from public sources and published under our editorial standards.